Diagnostics company Meridian Bioscience (NASDAQ:VIVO) plans to launch a new C. difficile test in Europe. C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening ...
MedCity News’ Brandon Glenn breaks down the recent FDA approval of Meridian Bioscience’s pediatric version of its C. difficile test on this week’s edition of Health Journal on ONN. Meridian said its ...
A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to testing for Clostridioides difficile (C. diff) guided by the principles of ...
Singulex’s Clarity C. diff toxin A/B assay, a rapid C. diff toxin test, has made its commercial debut, the company announced. “The Clarity toxin A/B assay offers a new approach to testing for C. diff ...
Researchers at Rhode Island Hospital (Providence) have developed a new test for Clostridium difficile able to distinguish between strains of varying virulence, according to research published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results